Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin.
The prognosis of patients with IgD myeloma is poorest among all types of multiple myeloma. We report a case of a patient with IgD myeloma who survived for an extraordinarily long period post-diagnosis (65 months). According to the new risk grouping of IgD myeloma (Shimamoto Y. et al., Eur. J. Haematol. 47, 262 (1991), he was classified as being in the high-risk group, with a zero percent expected 5-yr survival. Nevertheless, he survived for 65 months. We discuss the usefulness of interferon-alpha and erythropoietin for the treatment of IgD myeloma.
Hiyoshi
M
M
Department of Clinical Haematology, Osaka City University Medical School, Japan. mh1@msic.med.osaka-cu.ac.jp
Hashimoto
S
S
Ota
T
T
Nakao
T
T
Takubo
T
T
Tagawa
S
S
Tatsumi
N
N
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007072:Immunoglobulin D; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000503:physiopathology*; D011379:Prognosis; D013997:Time Factors
D000970:Antineoplastic Agents; D007072:Immunoglobulin D; D016898:Interferon-alpha; D004921:Erythropoietin